Efficacy and Safety of Timolol for TKI Induced Paronychia

Inclusion Criteria

• •1. Aged 18 years or above, either males or females.
• •2. Received EGFR-TKI, namely gefitinib, erlotinib, afatinib, osimertinib, amivantamab, dacomitinib and mobocertinib.
• •3. Paronychia (fingernails, toenails, or both) as an adverse event from EGFR-TKI use.
• •4. Written informed consent obtained from patient.